Convert Pharmaceuticals
Hypoxia-activated prodrugs against cancer treatment resistance.
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
€2.5m | Grant | ||
| Total Funding | 000k | ||
| EUR | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Notes (0)
More about Convert Pharmaceuticals
EditConvert Pharma is a clinical-stage biotech developing CP-506, a first-to-market hypoxia-activated prodrug targeting treatment resistance in solid tumors. Preclinical studies showed strong anti-tumor effects and a doubling of response to immunotherapies. Founder and CEO Prof. Dr. Philippe Lambin, a multi-entrepreneur (2 successful exits) and expert in personalised cancer therapy, aims to deliver Clin. Ph. IIa PoC in 2026 supported by AI and genetic biomarkers.
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.